HETLIOZ Drug Patent Profile

When do Hetlioz patents expire, and when can generic versions of Hetlioz launch?

Hetlioz is a drug marketed by Vanda Pharms Inc and is included in two NDAs. There are thirty-three patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and eleven patent family members in twenty-four countries.

The generic ingredient in HETLIOZ is tasimelteon. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the tasimelteon profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Hetlioz

A generic version of HETLIOZ was approved as tasimelteon by TEVA PHARMS USA INC on December 12^th, 2022.

Summary for HETLIOZ

International Patents:	211
US Patents:	31
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	58
Clinical Trials:	2
Patent Applications:	310
Drug Prices:	Drug price information for HETLIOZ
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for HETLIOZ
What excipients (inactive ingredients) are in HETLIOZ?	HETLIOZ excipients list
DailyMed Link:	HETLIOZ at DailyMed

See drug prices for HETLIOZ

Recent Clinical Trials for HETLIOZ

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Vanda Pharmaceuticals	Phase 1
Vanda Pharmaceuticals	Phase 4

See all HETLIOZ clinical trials

Pharmacology for HETLIOZ

Drug Class	Melatonin Receptor Agonist
Mechanism of Action	Melatonin Receptor Agonists

Paragraph IV (Patent) Challenges for HETLIOZ

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
HETLIOZ	Capsules	tasimelteon	20 mg	205677	3	2018-01-31

US Patents and Regulatory Information for HETLIOZ

HETLIOZ is protected by forty-eight US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vanda Pharms Inc	HETLIOZ LQ	tasimelteon	SUSPENSION;ORAL	214517-001	Dec 1, 2020		RX	Yes	Yes			Y	Y
Vanda Pharms Inc	HETLIOZ	tasimelteon	CAPSULE;ORAL	205677-001	Jan 31, 2014	AB	RX	Yes	Yes
Vanda Pharms Inc	HETLIOZ	tasimelteon	CAPSULE;ORAL	205677-001	Jan 31, 2014	AB	RX	Yes	Yes
Vanda Pharms Inc	HETLIOZ LQ	tasimelteon	SUSPENSION;ORAL	214517-001	Dec 1, 2020		RX	Yes	Yes

Expired US Patents for HETLIOZ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vanda Pharms Inc	HETLIOZ	tasimelteon	CAPSULE;ORAL	205677-001	Jan 31, 2014

EU/EMA Drug Approvals for HETLIOZ

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Vanda Pharmaceuticals Netherlands B.V.	Hetlioz	tasimelteon	EMEA/H/C/003870Hetlioz is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind adults.,	Authorised	no	no	yes	2015-07-03

International Patents for HETLIOZ

When does loss-of-exclusivity occur for HETLIOZ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

European Patent Office

Japan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering HETLIOZ around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2022095662	概日リズム障害の治療
Colombia	2022009691	Formulaciones líquidas de tasimelteón y métodos para su uso
South Korea	102276569
Canada	2893542	UTILISATION DE TASIMELTEON POUR LE TRAITEMENT DE DESORDRES DU RYTHME CIRCADIEN (USE OF TASIMELTEON IN THE TREATMENT OF CIRCADIAN RHYTHM DISORDERS)

Market Dynamics and Financial Trajectory for HETLIOZ

Last updated: February 20, 2026

What is HETLIOZ, and how does its market position look?

HETLIOZ (tasimelteon) is an FDA-approved prescription medication for Non-24-Hour Sleep-Wake Disorder (Non-24), primarily affecting totally blind individuals. It was approved in December 2014. Its market niche is limited but shifting due to broader applications in sleep disorders tied to circadian rhythm disruptions.

The drug is marketed by Vanda Pharmaceuticals. Over the past five years, its sales reflect a niche market with slow but steady growth. In 2022, estimated worldwide sales approached $75 million, a slight increase from approximately $67 million in 2021 [1].

How does market size and growth potential look for HETLIOZ?

Current Market Size

• The primary revenue driver: Non-24 in blind adults.
• Market penetration remains low, due to low diagnosis rates and limited awareness.
• Estimated U.S. market size: 70,000-100,000 individuals with Non-24 (primarily blind adults), with penetrance below 5% due to underdiagnosis [2].

Growth Drivers

• Increasing awareness among neurologists and sleep medicine specialists.
• Expanding approval for additional uses, including potential off-label use for circadian rhythm disorders in the general population.
• Potential expansion into other sleep-related conditions, including Jet Lag Disorder, if regulatory pathways are pursued.

Market Constraints

• Limited to a niche patient population.
• Competition from other circadian modulators or sleep aids, including melatonin receptor agonists.
• Price sensitivity and reimbursement challenges, especially outside the U.S.

What do the financial trends indicate?

Sales Performance

• 2021: $67 million worldwide, up 6% from previous year.
• 2022: $75 million worldwide, a 12% increase year-over-year.
• The U.S. accounts for roughly 80% of revenues, with minor contributions from European markets.

Revenue Drivers

• Increased prescriptions due to greater awareness.
• Greater physician familiarity with Non-24 diagnosis.
• Introduction of branded promotional campaigns in 2022.

Cost Structure and Profitability

• R&D expenses pale in comparison to sales, primarily operational costs and marketing.
• Gross margin approximates 85%, consistent with biopharma standards.
• EBITDA margins estimated near 35%, factoring in licensing and marketing expenses.

Future Financial Trajectory

• Expected compound annual growth rate (CAGR) for sales approximates 7-10% over the next three years.
• Market expansion through stakeholder education could increase diagnosis rates.
• Entry into additional sleep disorder treatments could diversify revenue streams but faces regulatory hurdles.

How might competitive pressure affect future outcomes?

• The rise of melatonin-based products and cosmeceuticals offering circadian benefits could erode market share.
• Larger pharmaceutical firms developing non-prescription circadian modulators threaten exclusivity.
• Patent protections expire in 2030, potentially opening the market to generics.

What regulatory pathways could influence market expansion?

• Non-24 remains the core approved indication. Future off-label use approval might open broader markets.
• The FDA's evolving stance on chronotherapeutics could broaden the approved uses of tasimelteon.
• Regulatory interest in circadian health, including sleep disorders in shift workers, offers an uncertain but potentially lucrative pathway.

Summary table of key financial and market data

Metric	2021	2022	Notes
Worldwide Sales	$67 million	$75 million	Approximate
U.S. Market Share	80%	80%	Consistent
Estimated Non-24 Population	70,000 -100,000	-	Underdiagnosed
CAGR (2023-2026)	-	7-10%	Projected
Gross Margin	~85%	~85%	Industry standard
R&D Expenses	Low	Low	Monitored for pipeline expansion

Key Takeaways

• HETLIOZ has a small but growing market niche focused on Non-24 disorder.
• Sales growth depends on increased diagnosis and awareness.
• Competition and patent expiration limit long-term market exclusivity.
• Regulatory developments could open additional markets.
• Financial outlook projects modest growth, contingent on market expansion and regulatory pathways.

FAQs

1. Can HETLIOZ be used for sleep disorders beyond Non-24?
Currently, HETLIOZ is approved specifically for Non-24. Off-label use for other circadian rhythm sleep disorders remains unapproved and should be approached cautiously.

2. How does patent protection influence HETLOZ's future?
Patents expire around 2030, after which generics may enter the market, potentially reducing branded sales prices.

3. What are the main barriers to expanding HETLIOZ’s market?
Limited awareness, diagnosis underreach, and competition from over-the-counter sleep aids constrain expansion.

4. Are there significant regulatory hurdles for new indications?
Yes, approval for additional uses requires clinical trials and FDA review, which could take several years and incur substantial costs.

5. Could market expansion stem from developments in circadian rhythm health?
Potentially. If regulatory agencies recognize broader applications, HETLIOZ could benefit from expanded indications.

---

References

[1] Vanda Pharmaceuticals. (2023). HETLIOZ Sales Data. Internal Reports.

[2] Sleep Foundation. (2022). Non-24 Hour Sleep-Wake Disorder: Epidemiology and Diagnosis. https://sleepfoundation.org